期刊
CYTOMETRY PART A
卷 87A, 期 11, 页码 1020-1028出版社
WILEY
DOI: 10.1002/cyto.a.22782
关键词
circulating tumor cells; in vivo flow cytometry; hepatocellular carcinoma; disease progression; treatment response
资金
- National Basic Research Program of China [2012CB966801, 2011CB910404]
- National Natural Science Foundation of China [81272574, 81172277, 30972949, 61227017]
- National Science Fund for Distinguished Young Scholar [61425006]
- National Key Sci-Tech Special Project of China [2012ZX10002-016]
- Special Fund for Guangdong Province Public Research and Capacity Building [2014B02021]
- Natural Science Foundation of Fujian Province [2014J01300]
- Innovation Research of Fujian Health Bureau [2012-CXB-7]
- Shanghai Science and Technology Committee [11DZ2211000]
- Scientific Research Foundation for High Level Talents in Nanfang Hospital of Southern Medical University
- Excellent Ph.D. Research Foundation of Fudan University
Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by rapid progression, poor prognosis, and frequent hematogenous metastasis. A minimally invasive diagnostic biomarker that can predict disease progression and treatment response would be of extraordinary benefit. Therefore, we have investigated whether the number of circulating tumor cells (CTCs) is correlated with disease progression and treatment response in HCC. Here we report that the number of CTCs, monitored by in vivo flow cytometry (IVFC), is strongly correlated with disease progression and treatment response in a highly metastatic orthotopic nude mouse model of green fluorescent protein (GFP)-labeled HCC. Sorafenib treatment reduces the number of CTCs significantly. The decreased number of CTCs is consistent with low lung metastasis. This study has demonstrated a considerable clinical value of CTCs as a biomarker in predicting disease progression and monitoring therapeutic efficacy in patients with HCC. (c) 2015 International Society for Advancement of Cytometry
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据